Table 1.
Effect of genome-wide homozygosity measures in Alzheimer’s disease for the joint analysis.
| Dataset | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| Beta (CI 95%) | P value | Beta (CI 95%) | P value | Beta (CI 95%) | P value | |
| FROH | 0.051 (0.023–0.078) | 3.25 × 10−4 | 0.044 (0.010–0.077) | 0.011 | 0.043 (0.009–0.076) | 0.013 |
| AVROH | 0.027 (0.000–0.055) | 0.051 | 0.074 (0.040–0.106) | 2.16 × 10−5 | 0.070 (0.037–0.104) | 3.91 × 10−5 |
| NROH | 0.043 (0.015–0.071) | 2.48 × 10−3 | 0.010 (−0.024–0.044) | 0.559 | 0.010 (−0.024–0.044) | 0.571 |
Model 1: adjusted per Cohort and PCs; Model 2: Adjusted by cohort, PCs, and age; Model 3: Adjusted by cohort, PCs, age and gender.
Results for the association of excess of homozygosity (FROH), average ROH lenght (AVROH), and number of ROH (NROH) with Alzheimer disease status.
OR, Odds ratio; with 95% confidence interval (CI 95%) and level of statistical significance (P value).
Association between homozygosity parameters and AD status, adjusted per Cohort, PCs, Age and Sex, was conducted in individuals with all available data; N = 19,253.